| ■ 英語タイトル：Insulin Delivery Devices Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
|
 | ■ 発行会社/調査会社：Mordor Intelligence
■ 商品コード：MOR23MAC114
■ 発行日：2023年1月23日
■ 調査対象地域：アメリカ、カナダ、フランス、ドイツ、イタリア、スペイン、イギリス、ロシア、メキシコ、ブラジル、日本、韓国、中国、インド、オーストラリア、ベトナム、マレーシア、インドネシア、フィリピン、タイ、サウジアラビア、イラン、エジプト、オマーン、南アフリカ
■ 産業分野：医療機器
■ ページ数：90
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
|
■ 販売価格オプション
（消費税別）
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Mordor Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。
*** レポート概要（サマリー）***Mordor Intelligence社の市場調査書によると、世界のインスリンデリバリー機器市場規模が、予測期間中（2022年-2027年）、CAGR 3％で拡大すると推測されています。本調査書では、インスリンデリバリー機器の世界市場について調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、管理機器別（インスリンポンプ、インスリン注射器、再利用可能型ペン用カートリッジ、使い捨て型ペン、その他）分析、地域別（アメリカ、カナダ、フランス、ドイツ、イタリア、スペイン、イギリス、ロシア、メキシコ、ブラジル、日本、韓国、中国、インド、オーストラリア、ベトナム、マレーシア）分析、競争状況、市場機会・将来動向など、以下の構成でお届けします。また、市場調査の対象企業には、Novo Nordisk AS、Sanofi SA、Eli Lilly and Company、Medtronic PLC、Insulet corporation、Ypsomed、Becton, Dickinson and Companyなどが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界のインスリンデリバリー機器市場規模：管理機器別
- インスリンポンプの市場規模
- インスリン注射器の市場規模
- 再利用可能型ペン用カートリッジの市場規模
- 使い捨て型ペンの市場規模
- その他インスリンデリバリー機器の市場規模
・世界のインスリンデリバリー機器市場規模：地域別
- 北米のインスリンデリバリー機器市場規模
アメリカのインスリンデリバリー機器市場規模
カナダのインスリンデリバリー機器市場規模
メキシコのインスリンデリバリー機器市場規模
…
- ヨーロッパのインスリンデリバリー機器市場規模
ドイツのインスリンデリバリー機器市場規模
イギリスのインスリンデリバリー機器市場規模
フランスのインスリンデリバリー機器市場規模
…
- アジア太平洋のインスリンデリバリー機器市場規模
中国のインスリンデリバリー機器市場規模
日本のインスリンデリバリー機器市場規模
インドのインスリンデリバリー機器市場規模
…
- 南米/中東のインスリンデリバリー機器市場規模
南アフリカのインスリンデリバリー機器市場規模
ブラジルのインスリンデリバリー機器市場規模
アルゼンチンのインスリンデリバリー機器市場規模
…
・競争状況
・市場機会・将来動向 |
The insulin delivery devices market is expected to register a CAGR greater than 3% over the forecast period, 2022-2027.
The COVID-19 pandemic substantially impacted the insulin delivery devices market. Type-1 diabetes patients are impacted more during COVID-19. People with diabetes have a weak immune system; hence, with COVID-19, the immune system gets weaker fast. People with diabetes may have more chances of serious complications than normal people. The manufacturers of insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. NovoNordisk stated on their website that “Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.” Doctors globally suggest diabetes patients check their diabetes levels more often to be careful. The intake of medicine has increased, leading to an increased usage of insulin delivery devices.
According to International Diabetes Federation (IDF), the adult diabetes population in 2021 was approximately 537 million, and this number is expected to increase by 643 million in 2030. Approximately 10% of the total diabetes population has Type-1 diabetes, and of this 10% of people, only 80-90% use insulin delivery devices; however, the usage of insulin is rising from time to time, and even Type-2 diabetes patients are using the insulin delivery devices during COVID-19.
Technological advancements in insulin delivery devices have increased over time for safer and more accurate insulin administration. Therefore, owing to the factors mentioned above, the studied market is anticipated to witness growth over the analysis period.
Insulin Delivery Devices Market Trends
Insulin Pump is Expected to Witness Growth Over the Forecast Period
An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.
Insulin pumps held 8% of the market share in the insulin delivery devices market in 2021, and it is expected to grow with a CAGR of 7% in the market, which is higher than other insulin delivery devices because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration.
Insulin pump therapy is a well-established insulin administration method for type 1 diabetes (T1DM). Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating.
The insulin infusion pumps reduce the large swings in blood glucose level, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
The market also benefits massively from the constant rise in the number of vendors, R&D activities, technological advancements in products, and the easy availability of advanced products globally. Moreover, favorable reimbursement scenarios in developed nations and a constant rise in awareness programs across developing economies are also working in favor of the market.
North America is Expected to Dominate the Insulin Delivery Devices Market
North America is expected to dominate the market owing to factors such as the easy availability of insulin delivery devices and high awareness among consumers.
The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in the United States indicate the increasing usage of diabetes care products. In the United States, according to the Academy of Managed Care Pharmacy, insulin pumps cost between USD 4,500 and USD 6,500 for individuals without insurance. The price varies depending upon the pump’s features, brand, and size. For example, the Accu-Chek Spirit Insulin Pump costs about USD 4,600 and includes a few features, such as software that allows readings to be downloaded to a personal digital assistant (PDA). The Minimed Paradigm 522 is more expensive, retailing at about USD 5,200, and includes more features, like continuous glucose monitoring. Some insurance plans will cover the cost of the pump. Patients with insurance may expect typical copay and coinsurance rates ranging from USD 5 to half of the pump’s total cost. Despite prices, diabetes patients in the United States use insulin delivery devices more often.
In 2021, the United States recorded the highest market share, with more than 20% in the insulin delivery devices market, followed by Japan and India. The rising diabetic population and the accessibility of technologically advanced devices contribute to the high market growth in the United States. According to Mordor Intelligence statistics, in 2021, around 37 million people in the United States had diabetes; among them, approximately 26.35 million patients were diagnosed, whereas about 10.1 million patients remained undiagnosed. Thus, the large patient base suffering from diabetes and its growing prevalence is expected to boost the growth in this region.
Therefore, owing to the factors described above, the growth of the market studied is anticipated in the North American Region.
Insulin Delivery Devices Market Competitor Analysis
The insulin delivery devices market is consolidated due to only a few major companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Novo Nordisk, Sanofi, Eli Lily and Company, Medtronic, Insulet, Ypsomped, Becton, Dickinson and Company, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 Market Segmentation
5.1 By Management Devices
5.1.1 Insulin Pump
5.1.1.1 Insulin Pump Devices (Value and Volume, 2016 – 2027)
5.1.1.2 Insulin Pump Reservoirs (Value and Volume, 2016 – 2027)
5.1.1.3 Infusion Sets (Value and Volume, 2016 – 2027)
5.1.2 Insulin Syringes (Value and Volume, 2016 – 2027)
5.1.3 Cartridges in reusable pens (Value and Volume, 2016 – 2027)
5.1.4 Disposable Pens (Value and Volume, 2016 – 2027)
5.1.5 Jet Injectors (Value and Volume, 2016 – 2027)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2016 – 2027)
5.2.1.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.1.2 Canada (Value and Volume, 2016 – 2027)
5.2.1.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.1.3 Rest of North America (Value and Volume, 2016 – 2027)
5.2.1.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2016 – 2027)
5.2.2.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2.2 Germany (Value and Volume, 2016 – 2027)
5.2.2.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2.3 Italy (Value and Volume, 2016 – 2027)
5.2.2.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2.4 Spain (Value and Volume, 2016 – 2027)
5.2.2.4.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2.5 United Kingdom (Value and Volume, 2016 – 2027)
5.2.2.5.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2.6 Russia (Value and Volume, 2016 – 2027)
5.2.2.6.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.2.7 Rest of Europe (Value and Volume, 2016 – 2027)
5.2.2.7.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2016 – 2027)
5.2.3.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.3.2 Brazil (Value and Volume, 2016 – 2027)
5.2.3.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.3.3 Rest of Latin America (Value and Volume, 2016 – 2027)
5.2.3.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2016 – 2027)
5.2.4.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.2 South Korea (Value and Volume, 2016 – 2027)
5.2.4.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.3 China (Value and Volume, 2016 – 2027)
5.2.4.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.4 India (Value and Volume, 2016 – 2027)
5.2.4.4.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.5 Australia (Value and Volume, 2016 – 2027)
5.2.4.5.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.6 Vietnam (Value and Volume, 2016 – 2027)
5.2.4.6.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.7 Malaysia (Value and Volume, 2016 – 2027)
5.2.4.7.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.8 Indonesia (Value and Volume, 2016 – 2027)
5.2.4.8.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.9 Philippines (Value and Volume, 2016 – 2027)
5.2.4.9.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.10 Thailand (Value and Volume, 2016 – 2027)
5.2.4.10.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2016 – 2027)
5.2.4.11.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.5 Middle-East
5.2.5.1 Saudi Arabia (Value and Volume, 2016 – 2027)
5.2.5.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.5.2 Iran (Value and Volume, 2016 – 2027)
5.2.5.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.5.3 Egypt (Value and Volume, 2016 – 2027)
5.2.5.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.5.4 Oman (Value and Volume, 2016 – 2027)
5.2.5.4.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.5.5 South Africa (Value and Volume, 2016 – 2027)
5.2.5.5.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
5.2.5.6 Rest of Middle-East (Value and Volume, 2016 – 2027)
5.2.5.6.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
6 MARKET INDICATORS
6.1 Type-1 Diabetes population (2016 – 2027)
6.2 Type-2 Diabetes population (2016 – 2027)
7 COMPETITIVE LANDSCAPE
7.1 Company profiles
7.1.1 Novo Nordisk AS
7.1.2 Sanofi SA
7.1.3 Eli Lilly and Company
7.1.4 Medtronic PLC
7.1.5 Insulet corporation
7.1.6 Ypsomed
7.1.7 Becton, Dickinson and Company
7.2 Company Share Analysis
7.2.1 Novo Nordisk AS
7.2.2 Sanofi SA
7.2.3 Eli Lilly and Company
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
*** 免責事項 ***https://www.globalresearch.co.jp/disclaimer/
